RA Capital Management’s Adicet Bio ACET Stock Holding History

RA Capital Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.06M	Sell	932,624 -250,000	-21%	-$1.97M	0.07%	77
2026 Q1	$8.05M	Buy	1,182,624 +234,375	+25%	+$1.75M	0.09%	77
2025 Q4	$7.98M	Buy	948,249 +476,936	+101%	+$5.27M	0.08%	61
2025 Q3	$6.11M	Hold	471,313	–	–	0.08%	60
2025 Q2	$4.6M	Hold	471,313	–	–	0.08%	58
2025 Q1	$5.69M	Hold	471,313	–	–	0.1%	76
2024 Q4	$7.25M	Hold	471,313	–	–	0.1%	79
2024 Q3	$10.9M	Hold	471,313	–	–	0.13%	66
2024 Q2	$9.12M	Hold	471,313	–	–	0.12%	67
2024 Q1	$17.7M	Buy	+471,313	New	+$19.5M	0.23%	68
2022 Q4	–	Sell	-128,711	Closed	-$29.3M	–	71
2022 Q3	$29.3M	Buy	+128,711	New	+$32.7M	0.62%	47

Other funds holding ACET

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

RA Capital Management's ACET Position: Q2 2026 in Review

RA Capital Management reduced its Adicet Bio (ACET) stake by 21% in Q2 2026, selling an estimated $1.97M and leaving 932,624 shares worth $8.06M. The position accounts for 0.07% of the portfolio, ranked #77.

RA Capital Management first reported a position in ACET in Q3 2022 and has held it in 11 quarters since. The position peaked at $29.3M in Q3 2022. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

RA Capital Management held 932,624 shares of Adicet Bio worth $8.06M as of Q2 2026.
RA Capital Management sold 250,000 Adicet Bio shares in Q2 2026, an estimated $1.97M.
Adicet Bio made up 0.07% of RA Capital Management's portfolio in Q2 2026, its #77 holding.
RA Capital Management first reported a position in Adicet Bio in Q3 2022 and has held it in 11 quarters since.
RA Capital Management's Adicet Bio position peaked at $29.3M in Q3 2022.
56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.